HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
Case: Sequencing ADCs in a patient with HR+, HER2‑low metastatic disease
Dr Huppert reviews a 57‑year‑old treated through endocrine lines then T‑DXd, later ribociclib, rucaparib, ribulin, and now Dato‑DXd with good tolerance.
Play episode from 30:52
Transcript
